NEW YORK, NY--(Marketwire - Aug 8, 2012) - Plandai Biotechnology, Inc. (OTCQB: PLPL) has received a "BUY" Rating in the most recent KonLin Letter, authored by Konrad Kuhn. The Konlin Letter is a unique service that recommends 5 low-priced stock selections each month including a featured stock of the month.
According to The KonLin Letter, Plandai's income is projected to reach $27 million in 2012-13 and accelerate to $90 million in 5 years time. This projection is based in part on the $29 billion U.S. Nutritional Supplement Industry which is growing at almost 5.5% annually and Plandai controlling every aspect of their process, from growing raw material to producing their extracts in-house.
Plandai Biotechnology, Inc. focuses on the farming of whole fruits, vegetables and live plant material and the production of proprietary functional foods and botanical extracts for the health and wellness industry.
Other active stocks in the functional foods and supplements market are GNC Holdings, Inc. (NYSE: GNC), Vitamin Shoppe, Inc. (NYSE: VSI) and Whole Foods Market, Inc. (NASDAQ: WFM).
This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Information, opinions and analysis contained herein are based on sources deemed to be reliable and are subject to change without notice. A third party has hired and paid OTC Report one thousand two hundred and ninety five dollars for the publication and circulation of this news release. Accordingly, certain information included herein may be forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. However, no representation, expressed or implied, is made as to the accuracy, completeness or correctness. In light of the above, we accept no liability for any losses arising from an investor's reliance on or use of this report. We do not and have not had any ownership interest in said third party of any kind.